Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.46 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.44 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.44 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.44 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | GPR183 | P32249 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL4250868 | 1.00 | HCRTR2 (0.47) | HCRTR2HCRTR1NPC1KMT2ACHRM2 | |
| Fumaric Acid SCHEMBL4245795 | 0.86 | CHRM2 (0.56) | HCRTR2HCRTR1NPC1KMT2ACHRM2 | |
| Fumaric Acid SCHEMBL4245791 | 0.86 | CHRM2 (0.56) | HCRTR2HCRTR1NPC1KMT2ACHRM2 | |
| Fumaric Acid SCHEMBL4250550 | 0.85 | CHRM2 (0.45) | HCRTR2HCRTR1NPC1KMT2ACHRM2 | |
| Fumaric Acid SCHEMBL4250537 | 0.85 | CHRM2 (0.45) | HCRTR2HCRTR1NPC1KMT2ACHRM2 | |
| SCHEMBL4246922 | 0.84 | NPC1 (0.53) | HCRTR2HCRTR1NPC1KMT2ABCHE | |
| SCHEMBL3145945 | 0.83 | CHRM2 (0.52) | NPC1KMT2ACHRM2HTR1ASLC6A4 | |
| Hydrochloric Acid SCHEMBL4250386 | 0.82 | CHRM2 (0.48) | NPC1KMT2ACHRM2HTR1ASLC6A4 | |
| Fumaric Acid SCHEMBL4248087 | 0.81 | CHRM2 (0.45) | HCRTR2HCRTR1NPC1KMT2ACHRM2 | |
| Fumaric Acid SCHEMBL4248079 | 0.81 | CHRM2 (0.45) | HCRTR2HCRTR1NPC1KMT2ACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076325-B2 | 1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2011-12-13 | — | — | US | disclosed |
| US-20090069296-A1 | 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069296-A1 | 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them | OXER1, NR1H3, OXSR1 | KMT2A 1570/4885CHRM2 72/4885HTR1A 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.